Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers
Guardant Health, Inc. (NASDAQ:GH) has introduced major upgrades to its Guardant360 Liquid biopsy test, significantly expanding its cancer biomarker detection and subtyping abilities. Utilizing the Guardant Infinity platform and AI-driven analysis, the test now offers comprehensive multiomic profiling from a simple blood draw.
A patient viewing their medical diagnosis on a digital healthcare ecosystem.
The enhanced test helps doctors quickly exclude actionable mutations in lung and colorectal cancers, identify cancer origins when unknown, and accurately classify breast and lung cancer subtypes through tumor methylation patterns. It also integrates pharmacogenomic data to guide safe drug use, detects viruses like HPV and EBV affecting treatment, assesses Homologous Recombination Deficiency (HRD) for targeted therapies, and uses HLA genotyping to inform therapy choices and clinical trial options.
Guardant Health, Inc. (NASDAQ:GH)'s co-CEO Helmy Eltoukhy highlighted that this blood-based test provides vital tumor insights without needing tissue samples, delivering results within seven days and enabling faster, smarter cancer treatment decisions.
While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
30 minutes ago
- Forbes
How SMCI Stock Is Riding Nvidia's Blackwell Wave
Super Micro Computer stock (NASDAQ:SMCI) increased by nearly 5% during Friday's trading session and stands approximately 35% higher over the past month. Multiple factors have contributed to the stock's rise in recent weeks, such as significant analyst upgrades and the announcement of a $20 billion partnership with Saudi data center company DataVolt. There has also been speculation regarding a possible short squeeze in SMCI stock. As of May 2025, around 20% of SMCI's outstanding shares were held in short positions. This level of short interest could lead to a short squeeze, compelling short sellers to repurchase shares to cover their positions. Additionally, Nvidia disclosed a solid set of Q1 results last week, which reflects positively on SMCI. Nvidia stated that the rollout of its new Blackwell GPU is progressing well, with these latest products now making up 70% of data center revenue in the previous quarter, indicating that Blackwell sales have roughly doubled from the previous quarter. Super Micro's server solutions are closely linked to Nvidia's GPU ecosystem and roadmap. The company has generally been more agile than its peers in delivering server systems that align with Nvidia's latest products, thanks to its modular system designs, advanced cooling and power systems, and close collaboration with Nvidia regarding software and hardware integration. SMCI is likely to reap substantial rewards as a primary provider of custom, high-density GPU servers for Nvidia's data center customers as the deployment of Blackwell continues to expand. So, is SMCI stock appealing following the recent surge? We consider SMCI stock to be reasonably valued at its current market price of $43, although there are some reservations. We reach this conclusion by comparing the current valuation of SMCI stock to its recent operating performance as well as its existing and historical financial health. Our evaluation of Super Micro Computer across key metrics of Growth, Profitability, Financial Stability, and Resilience During Downturns indicates that the company maintains a strong operating performance and financial status, as outlined below. However, for those looking for potential upside with lower volatility than individual stocks, the Trefis High Quality Portfolio offers an alternative, having outperformed the S&P 500 and achieving returns exceeding 91% since its inception. When considering what you pay per dollar of sales or profit, SMCI stock appears slightly undervalued in comparison to the broader market. • Super Micro Computer holds a price-to-sales (P/S) ratio of 1.2 in contrast to a figure of 3.0 for the S&P 500 • Additionally, the company's price-to-free cash flow (P/FCF) ratio is 174.4 relative to 20.5 for the S&P 500 • Furthermore, it has a price-to-earnings (P/E) ratio of 22.4 compared to the benchmark's 26.4 The revenues of Super Micro Computer have expanded significantly over the past few years. • Super Micro Computer has experienced an average revenue growth rate of 68.1% in the last 3 years (compared to a 5.5% increase for the S&P 500) • Its revenues have increased by 82.5% from $9.3 billion to $21 billion in the past 12 months (relative to a 5.5% growth for the S&P 500) • Moreover, its quarterly revenues rose 19.5% to $5.7 billion in the most recent quarter from $3.7 billion a year prior (compared to a 4.8% improvement for the S&P 500) Super Micro Computer's profit margins are significantly lower than those of most companies within the Trefis coverage universe. • Super Micro Computer's Operating Income over the past four quarters amounted to $1.3 billion, which translates to a low Operating Margin of 6.1% (compared to 13.2% for the S&P 500) • SMCI's Operating Cash Flow (OCF) during this timeframe was $148 million, reflecting a very low OCF Margin of 0.7% (in contrast to 14.9% for the S&P 500) • For the last four quarters, SMCI's Net Income was $1.2 billion — indicating a low Net Income Margin of 5.3% (compared to 11.6% for the S&P 500) Super Micro Computer's balance sheet appears robust. • Super Micro Computer's Debt stood at $2.5 billion at the conclusion of the most recent quarter, with its market capitalization being $25 billion (as of 6/3/2025). This results in a healthy Debt-to-Equity Ratio of 9.7% (in contrast to 19.9% for the S&P 500). [Note: A lower Debt-to-Equity Ratio is preferred] • Cash (inclusive of cash equivalents) constitutes $2.5 billion of Super Micro Computer's total assets, which amount to $11 billion. This leads to a strong Cash-to-Assets Ratio of 23.6% (relative to 13.8% for the S&P 500) SMCI stock has demonstrated more resilience than the benchmark S&P 500 index during a few recent downturns. With investors hoping for a smooth landing for the U.S. economy, how severe could the impact be if another recession occurs? Our dashboard How Low Can Stocks Go During A Market Crash illustrates how key stocks performed during and after the last six market crashes. • SMCI stock declined 34.5% from a peak of $35.33 on 7 August 2023 to $23.15 on 21 September 2023, compared to a peak-to-trough decrease of 25.4% for the S&P 500 • The stock fully recovered to its pre-Crisis peak by 19 January 2024 • Since then, the stock has risen to a high of $118.81 on 13 March 2024 and is currently trading at approximately $43 • SMCI stock fell 45.8% from a high of $2.95 on 5 February 2020 to $1.60 on 18 March 2020, versus a peak-to-trough decline of 33.9% for the S&P 500 • The stock fully recovered to its pre-Crisis peak by 8 June 2020 • SMCI stock dropped 66.3% from a high of $1.14 on 5 June 2007 to $0.39 on 13 November 2008, compared to a peak-to-trough decline of 56.8% for the S&P 500 • The stock fully recovered to its pre-Crisis peak by 22 December 2009 Super Micro Computer displays a mixed fundamental outlook. On one hand, its growth trajectory is exceptionally strong, and its financial stability continues to be sound, with the company also demonstrating resilience during downturns. However, profitability remains a significant weakness. Margins are considerably below those of competitors and have been on a downward trend. Compounding investor worries are governance issues, including previous allegations of accounting irregularities, delays in SEC filings, and scrutiny from short sellers. Although the company has made efforts to address these concerns, a cautious approach is advisable when assessing SMCI stock. While it may not appear that there is significant upside to SMCI stock, the Trefis Reinforced Value (RV) Portfolio has outperformed its all-cap stock benchmark, comprising the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices, delivering strong returns for investors. Why is that? The quarterly rebalanced blend of large-, mid-, and small-cap RV Portfolio stocks offers a reactive approach to capitalizing on favorable market conditions while mitigating losses in declining markets, as detailed in RV Portfolio performance metrics.
Yahoo
41 minutes ago
- Yahoo
Why AI Stock Broadcom Topped the Market on Tuesday
It announced that it started shipping its latest AI chip. The chip is a vast improvement over its predecessor, the company said. Meanwhile, two analysts published bullish updates on the stock. These 10 stocks could mint the next wave of millionaires › A new product rollout is always an attention-grabbing piece of news in the corporate world, and that goes double for businesses involved with artificial intelligence (AI). On Tuesday, specialty chip maker Broadcom (NASDAQ: AVGO) announced it began shipping an advanced networking chip. Investors greeted this by pushing the company's stock up by more than 3% that trading session. That gain easily trounced the 0.6% increase of the S&P 500 index. Broadcom's Tomahawk 6 switch series is now on its way to the market, the company announced that morning (a switch, also known as a switching chip, is a highly specialized component that handles data trafficking through a computer network). According to Broadcom, the Tomahawk 6 boasts double the bandwidth of any switch available on the market just now. It's designed to handle the comparably much higher resource needs of artificial intelligence (AI) functionalities. The company said its new product has an unrivaled set of AI routing features and interconnect options. The announcement came two days before Broadcom is slated to publish its fiscal second quarter of 2025 earnings. What also helped the stock rise was a pair of bullish new analyst notes released in anticipation of those results. Both Citigroup's Christopher Danley and JPMorgan Chase's Harlan Sur maintained their equivalent of buy recommendations in their respective updates. Danley went as far as to raise his price target on the stock significantly to $276 per share from his previous $210. According to reports, Danley believes Broadcom will top analyst estimates for the quarter, especially considering that AI is an important driver of its sales, and demand for the technology remains scorching. I'd be as bullish as those two gentlemen; Broadcom is very well placed to be a main supplier expanding AI capabilities, and its fundamentals should reflect that going forward. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $356,261!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,291!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $657,385!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 2, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Why AI Stock Broadcom Topped the Market on Tuesday was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'
We recently published a list of . In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: 'You know, look, it doesn't make any money. I've been waiting for it to do something, break out. I just don't know if it has the horses.' A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab. Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company: 'I looked at Arrowhead recently and I didn't see that much. You know, everyone's so excited about it. I don't get that. I have been saying that it's absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I'm not gonna endorse it for anything other than speculation.' For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
